Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
The Indian drugmaker highlighted resilience in its domestic formulations business. This segment continued to deliver solid performance amid broader market conditions.
Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.
Reported by AI
A sample of 164 companies reported revenue growth of 17.5 percent and net profit growth of 14.5 percent in the first quarter. The figures mark the fastest revenue expansion in at least nine quarters and the second straight quarter of double-digit profit gains.
Dr Reddy's Laboratories expects a gradual recovery in the current fiscal year after a profit decline last year. Growth in India, Europe, and emerging markets is offsetting pressures in the US business. New product launches and margin improvements are set to support expansion.
Reported by AI
Nestle India shares hit a record high following robust growth in the June quarter. Revenue rose 25.2 percent year-on-year as demand remained firm. The company expects healthy sales to continue amid premium products and innovation.